Feb 25, 2019
Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Feb 11, 2019
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Jan 15, 2019
Southeast Asia Atopic Dermatitis Therapeutics Markets to 2024 - How will Novel IL-4Ra Inhibitor Therapy Dupixent, which Holds First-to-Market Advantage, Contribute to Growth
Jan 07, 2019
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Nov 07, 2018
Sanofi/Regeneron's Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
Nov 06, 2018
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Oct 31, 2018
Sanofi Q3 2018 Performance Confirms Return to Growth
Oct 31, 2018
Atopic Dermatitis Drugs Market Size Worth $6.41 Billion by 2022: Grand View Research, Inc.
Oct 19, 2018
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 16, 2018
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Sep 15, 2018
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
May 21, 2018
New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
May 16, 2018
Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 03, 2018
Sanofi/Regeneron's Dupixent, the Darling of Atopic Dermatitis
Mar 02, 2018
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Feb 08, 2018
First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent(TM), now available in Canada
Feb 02, 2018
Growth of Sanofi-Regeneron's Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer's Eucrisa Carves a Niche with Younger Patients
Jan 22, 2018
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Jan 08, 2018
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
Dec 13, 2017
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day